World Genomic Cancer Panel and Profiling Market Research Report 2022

DublinAnd January 13, 2022 /PRNewswire/ – “The Commission on Cancer Genomes and Markets Profiling by Cancer and Germline/Somatic Type with Examination of Potential Market Size, Prediction/Ad Hoc Analysis, Implementation and Advisory Evidence 2021-2025” has been added to ResearchAndMarkets.com Show.

The market is exploding as doctors use all the information they can get in the fight against cancer. There is a lot of information to be obtained. But the COVID-19 pandemic has affected the market. Find out how in this comprehensive report.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of 2020 US Medicare payment schedules to help understand test pricing in detail. Anticipate the demand for new testing systems or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan the growth of clinical facilities.

Cancer gene panels and genetic profiling are rapidly changing the diagnosis and treatment of cancers. The market is getting out of a niche and into the mainstream as oncologists routinely begin using information on hundreds of cancer-related genes.

Comprehensive panels, genotyping, high-risk breast cancer panels. Learn all about how players compete for a position in a market created from scratch. And some players have already taken the initiative. It is a dynamic market condition with huge opportunity where the right diagnosis with the right support can command excellent prices. And science is developing at the same time and regularly creating new opportunities. And the cost of sequencing continues to drop.

Main topics covered:

Cancer Profiles & Boards Recent Developments

  • Biocartis Collaborates with GeneproDx, Endpoint Health on Idilla Platform Tests
  • Wales For routine screening of cancer patients using the Yourgene Elucigene test
  • Signs of metastatic cancer identified in the WGS clinical study
  • Stitch Bio Bets on CRISPR
  • Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
  • Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Accompaniment Dx
  • Progress and challenges in liquid biopsy reimbursement
  • Israeli startups react high 6 million dollars
  • Invitae and ArcherDX combine to deliver precision oncology offerings
  • Supporting MD Anderson Precision Oncology’s decision to use the Philips Information Solution
  • NeoGenomics, Lilly Oncology partner for thyroid cancer testing program
  • Germline results guide accurate treatment in advanced cancer
  • FDA clears cancer genome profiling suite from personalized genome diagnoses
  • ArcherDX, Prime Minister Collaborate to Evaluate Cancer Genetic Sequencing Test
  • Labs reporting cancer risk mutations from tumor testing
  • Users begin integrating genomic data to support clinical decision
  • Fujitsu improves efficiency in genetic medicine for cancer
  • Thermos Fisher Automated sequencer to deliver same-day pan-cancer test results
  • Comprehensive genetic testing for all breast cancer patients
  • Exact science buys genetic health
  • Breast cancer polygenic liquid panel
  • We strive to advance early detection of multiple types of cancer
  • New gene panel identifies high-risk prostate cancer
  • Guardant Health Liquid Biopsy Test to be Covered by EviCore
  • Biocept’s Liquid Biopsy Partnership Offering Adds Several Key Services
  • Natera markets whole-exome sequencing of tumors from plasma
  • Inivata completes £39.8m Series B funding round
  • Bio-Rad Clinical ddPCR Test, Diagnostic System FDA Clearance
  • CellMax, Medigen Biotech’s partner in colorectal cancer clinical trials
  • Biodesix acquires Integrated Diagnostics
  • Predicine, Kintor Pharmaceuticals’ partner in clinical trials, CDx

Market trends

level of care

  • DX’s Companion
  • immune tumors
  • legal responsibility
  • aging population

Factors that limit growth

  • state of knowledge
  • Genetic snow storm.
  • protocol resistance
  • Organizing and covering
  • Hardware and automation
  • Tools are the key to market share
  • Bioinformatics plays a role

Diagnostic technology development

  • Next generation sequencing fuels a revolution
  • The single cell genome changes the picture
  • Pharmacogenomics blurs diagnosis and treatment
  • CGES Quiz, Brave New World
  • Biochips / Giant Magnetic Resistivity Based Assay

Market Overview

Players in a dynamic market

  • Academic Research Lab
  • Diagnostic Test Developer
  • hardware supplier
  • Detector distributor and supplier
  • Independent Test Lab
  • National/Regional General Laboratory
  • hospital lab
  • Doctor’s office laboratories
  • review body
  • Certification body

genomics

  • carcinogenesis
  • Chromosomes, genes and epigenetics
  • chromosomes
  • genes
  • Epigenetics
  • cancer genes
  • germline vs somatic
  • Gene panels, single and multiplex gene assays
  • genomic profiling
  • Comprehensive examination
  • Clinical role change
  • Cancer Screening Market Opportunities

Cancer Management vs. Diagnosis

  • The role of risk assessment
  • diagnose
  • Management
  • watching

Stages of adoption – looking to the future

Industry structure plays a role

  • hospital test share
  • economic scale
  • Hospital in front of the central lab
  • Doctor’s office lab
  • Doctor and at the point of care

Profiles of the main players

  • Abbott Diagnostics
  • AccuraGen . Company
  • Acuamark Diagnostics
  • Admira Health, LLC
  • Agena Bioscience, Inc.
  • Agilent
  • Pain Diagnostics
  • Amoy Diagnostics Co., Ltd.
  • DX anchor
  • ANGLE plc
  • ApoCell, Inc.
  • Archer DX, Inc
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraka Genetic Laboratories
  • Beckmann CoulterInc.
  • Becton, Dickinson & Co
  • BGI Genomics Ltd.
  • Bioarray genetics
  • Biocartes
  • Biospet, you
  • Biodesix Corporation
  • biofluids
  • bioMerieux Diagnostics
  • Pioneer Company
  • Bio-Rad Laboratories, Inc.
  • bio tech
  • Bioview
  • genetics diagram
  • Polydex
  • Nordic genomics
  • Caris . Molecular Diagnostics
  • Cell Max’s life
  • Cepheid (now Danaher)
  • Cronex Biomedical
  • Blood circulation
  • Clinical Genomics
  • seneveo
  • Cytolumina Technologies Corp
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnostics
  • Diagnologix LLC
  • Enzo Life Sciences, Inc
  • epic science
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • exosome science
  • Fluidigm Corp
  • Flow Biological Sciences
  • Medical Foundation
  • Freenom
  • fulgent genetics
  • GeneFirst Ltd.
  • Health Genetron (BeijingLtd.
  • genomic health
  • Jellopi Nanomedicine
  • Grail, Inc.
  • guard health
  • hansa
  • HeiScreen
  • Helomitics
  • Horizon Discovery 224 i Silat
  • Illumina
  • Incell DX
  • Enivata
  • call company
  • Integrated Diagnostics
  • Janssen Diagnostics
  • Oncology Loxo
  • MDNA LIFE SCIENCES, INC
  • MDx Health
  • Menarini Silicon Bio Systems
  • Millipore Sigma
  • Miltenyi Biotec
  • mir scientific
  • MD Molecular
  • Myriad Genetics / Myriad RBM
  • NantHealth, Inc.
  • natira
  • NeoGenomics
  • The new science of oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • neoplastic
  • Unko DNA
  • Oxford Nanopore Technologies
  • Birkin Elmer
  • Personal genome diagnosis
  • Precision Med
  • Promega
  • Qiagen GmbH
  • Quidel
  • Rarecells SAS
  • rare
  • Biological Sciences Resolution, Inc
  • Roche Molecular Diagnostics
  • screensl
  • Siemens Healtheners
  • simfo GmbH
  • Singlera Genomics Inc
  • SRI International
  • Sysmex Inostics
  • Time Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Flourish early detection
  • Trovagen
  • Will

For more information on this report, visit https://www.researchandmarkets.com/r/4kf60a

Media contact:

Research and Markets
Laura Wooddirector, mentor
[email protected]

For EST office hours, call +1-917-300-0470
For the US/Canada, call toll free +1-800-526-8630
For GMT office hours, call +353-1-416-8900

US Fax: 607-646-1907
Fax (outside the US): +353-1-481-1716

SOURCE Research & Markets

.

Leave a Comment